A multi-acid, antioxidant delivery approach that promises boost in radiance and texture without PIH. Worth a look for patients with FST V–VI Facial rejuvenation that's both effective and safe in…
Read More
Dupilumab in Diverse Skin — Are Adverse Events Really the Same? Atopic dermatitis isn’t one-size-fits-all: chronic type 2 inflammation, barrier dysfunction, and S. aureus colonization are core features, but presentation…
Read More
Moderate Evidence Points To Safety And Quality-Of-Life Gains In Hard-To-Treat Patients We’re pulling this article from our vault because it’s one of our most popular reads, and with good reason.…
Read More
Catch Up on the Latest Think about the last time you saw real-world data reshape your treatment approach—what if you discovered that one of our most trusted biologics behaves differently…
Read More
A Closer Look at Alopecia Areata in Black Patients: Are We Missing Key Diagnostic Clues? Alopecia areata (AA) is more prevalent in patients with skin of color —but how well…
Read More
Hyperpigmentation Patients Report Low Satisfaction and Limited Awareness of Treatment Options A new cross-sectional survey reveals that hyperpigmentation, especially among patients with deeper skin tones, continues to be a significantly…
Read More
Curated by the JDD Editors Missed any of our July highlights? As the official partner of the Skin of Color Update , July is our “Bridging the Gap in Dermatology”…
Read More
Lotion or Cream? A Fresh Look at Moisturizer Efficacy in Dry Skin Dry skin is more than just a nuisance, it’s a clinical challenge that affects comfort, barrier function, and,…
Read More
Catch Up on July’s Latest Case Report on Pincer Nail Relief Pincer nail deformity isn’t just unsightly, it’s painful, persistent, and notoriously difficult to treat. While braces and surgery are…
Read More
June 25 marks World Vitiligo Day, a global recognition of a condition that affects approximately 0.5-2% of the population worldwide. Though non-life-threatening, vitiligo carries a profound psychosocial burden, disproportionately affecting…
Read More
Did you miss it? By 2044, people with skin of color (SOC) will make up the majority of the U.S. population—but dermatology still lags behind in addressing their unique needs.…
Read More
Featured Article Acanthosis nigricans disproportionately affects individuals with darker skin tones, yet no FDA-approved treatment currently exists. As the demand for effective therapies grows, the dermatology community faces a critical challenge:…
Read More
